Can Follow-up be Avoided for Probably Benign US Masses with No Enhancement on MRI?

ABSTRACT:

Objectives

To assess whether no enhancement on pre-treatment MRI can rule out malignancy of additional US mass(es) initially assessed as BI-RADS 3 or 4 in women with newly diagnosed breast cancer.

Methods

This retrospective study included consecutive women from 2010-2018 with newly diagnosed breast cancer; at least one additional breast mass (distinct from index cancer) assigned a BI-RADS 3 or 4 on US; and a bilateral contrast-enhanced breast MRI performed within 90 days of US. All malignant masses were pathologically proven; benign masses were pathologically proven or defined as showing at least 2 years of imaging stability. Incidence of malignant masses and NPV were calculated on a per-patient level using proportions and exact 95% CIs.

Results

In 230 patients with 3

SUBMITTER: Avendano D 

PROVIDER: S-EPMC7855658 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature